sellWeak cluster of 210b5-1 plan
BERNS PAUL L sold $23k of NMRA
See Remarks at Neumora Therapeutics, Inc.. 13,871 shares at an average of $1.69, traded Feb 18, 2025, filed Feb 20, 2025.
Warning score
3Value
$23k
13,871 shares
Holdings after
7,405,004
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001610717-25-000031, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -13,871 | $1.69 | $23k | 7,405,004 | Feb 20, 2025 |
Related signals
Other insiders at Neumora Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | Aurora Daljit Singh Chief Strategy Officer | $14k | 8,565 | |
| 23Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | Fust Matthew K director | $371k | 21,788 | |
| 15Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | Lenz Robert A. Head of R&D | $208k | 13,823 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.